Exosomes, MDSCs and Tregs: A new frontier for GVHD prevention and treatment
The development of graft versus host disease (GVHD) represents a long-standing complication of allogeneic hematopoietic cell transplantation (allo-HCT). Different approaches have been used to control the development of GVHD with most relying on variations of chemotherapy drugs to eliminate allo-reac...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1143381/full |
| _version_ | 1797857905023647744 |
|---|---|
| author | Nicholas J. Hess Nicholas J. Hess John A. Kink John A. Kink Peiman Hematti Peiman Hematti |
| author_facet | Nicholas J. Hess Nicholas J. Hess John A. Kink John A. Kink Peiman Hematti Peiman Hematti |
| author_sort | Nicholas J. Hess |
| collection | DOAJ |
| description | The development of graft versus host disease (GVHD) represents a long-standing complication of allogeneic hematopoietic cell transplantation (allo-HCT). Different approaches have been used to control the development of GVHD with most relying on variations of chemotherapy drugs to eliminate allo-reactive T cells. While these approaches have proven effective, it is generally accepted that safer, and less toxic GVHD prophylaxis drugs are required to reduce the health burden placed on allo-HCT recipients. In this review, we will summarize the emerging concepts revolving around three biologic-based therapies for GVHD using T regulatory cells (Tregs), myeloid-derived-suppressor-cells (MDSCs) and mesenchymal stromal cell (MSC) exosomes. This review will highlight how each specific modality is unique in its mechanism of action, but also share a common theme in their ability to preferentially activate and expand Treg populations in vivo. As these three GVHD prevention/treatment modalities continue their path toward clinical application, it is imperative the field understand both the biological advantages and disadvantages of each approach. |
| first_indexed | 2024-04-09T21:04:24Z |
| format | Article |
| id | doaj.art-b3da5751827846b1b1dd0866e6faa4db |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-09T21:04:24Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-b3da5751827846b1b1dd0866e6faa4db2023-03-29T04:42:50ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-03-011410.3389/fimmu.2023.11433811143381Exosomes, MDSCs and Tregs: A new frontier for GVHD prevention and treatmentNicholas J. Hess0Nicholas J. Hess1John A. Kink2John A. Kink3Peiman Hematti4Peiman Hematti5Division of Hematology, Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, United StatesUniversity of Wisconsin Carbone Cancer Center, Madison, WI, United StatesDivision of Hematology, Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, United StatesUniversity of Wisconsin Carbone Cancer Center, Madison, WI, United StatesDivision of Hematology, Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, United StatesUniversity of Wisconsin Carbone Cancer Center, Madison, WI, United StatesThe development of graft versus host disease (GVHD) represents a long-standing complication of allogeneic hematopoietic cell transplantation (allo-HCT). Different approaches have been used to control the development of GVHD with most relying on variations of chemotherapy drugs to eliminate allo-reactive T cells. While these approaches have proven effective, it is generally accepted that safer, and less toxic GVHD prophylaxis drugs are required to reduce the health burden placed on allo-HCT recipients. In this review, we will summarize the emerging concepts revolving around three biologic-based therapies for GVHD using T regulatory cells (Tregs), myeloid-derived-suppressor-cells (MDSCs) and mesenchymal stromal cell (MSC) exosomes. This review will highlight how each specific modality is unique in its mechanism of action, but also share a common theme in their ability to preferentially activate and expand Treg populations in vivo. As these three GVHD prevention/treatment modalities continue their path toward clinical application, it is imperative the field understand both the biological advantages and disadvantages of each approach.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1143381/fullgraft vs host diseaseexosomesregulatory T cellsmyeloid derived suppressor cell (MDSC)mesenchymal stromal cell (MSC) |
| spellingShingle | Nicholas J. Hess Nicholas J. Hess John A. Kink John A. Kink Peiman Hematti Peiman Hematti Exosomes, MDSCs and Tregs: A new frontier for GVHD prevention and treatment Frontiers in Immunology graft vs host disease exosomes regulatory T cells myeloid derived suppressor cell (MDSC) mesenchymal stromal cell (MSC) |
| title | Exosomes, MDSCs and Tregs: A new frontier for GVHD prevention and treatment |
| title_full | Exosomes, MDSCs and Tregs: A new frontier for GVHD prevention and treatment |
| title_fullStr | Exosomes, MDSCs and Tregs: A new frontier for GVHD prevention and treatment |
| title_full_unstemmed | Exosomes, MDSCs and Tregs: A new frontier for GVHD prevention and treatment |
| title_short | Exosomes, MDSCs and Tregs: A new frontier for GVHD prevention and treatment |
| title_sort | exosomes mdscs and tregs a new frontier for gvhd prevention and treatment |
| topic | graft vs host disease exosomes regulatory T cells myeloid derived suppressor cell (MDSC) mesenchymal stromal cell (MSC) |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1143381/full |
| work_keys_str_mv | AT nicholasjhess exosomesmdscsandtregsanewfrontierforgvhdpreventionandtreatment AT nicholasjhess exosomesmdscsandtregsanewfrontierforgvhdpreventionandtreatment AT johnakink exosomesmdscsandtregsanewfrontierforgvhdpreventionandtreatment AT johnakink exosomesmdscsandtregsanewfrontierforgvhdpreventionandtreatment AT peimanhematti exosomesmdscsandtregsanewfrontierforgvhdpreventionandtreatment AT peimanhematti exosomesmdscsandtregsanewfrontierforgvhdpreventionandtreatment |